Journal of Pain Research (Apr 2021)
Ubrogepant in the Acute Management of Migraine: A Narrative Review
Abstract
Chia-Chun Chiang,1 Juliana H VanderPluym2 1Department of Neurology, Mayo Clinic, Rochester, MN, USA; 2Department of Neurology, Mayo Clinic, Scottsdale, AZ, USACorrespondence: Juliana H VanderPluym Email [email protected]: Ubrogepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that received Food and Drug Administration (FDA) approval for the acute treatment of migraine with and without aura in adults. The ACHIEVE I and ACHIEVE II Phase III clinical trials showed that ubrogepant was superior to placebo for pain freedom and freedom of the most bothersome migraine-associated symptom at 2 hours after medication intake. The 52-week open label extension of the Phase III trials demonstrated safety of ubrogepant. A real-world study conducted at a tertiary headache center also confirmed the efficacy and safety of ubrogepant. Adverse event rates were higher in the real-world population. Studies are needed to evaluate its long-term efficacy and safety, especially in the setting of co-administration with other CGRP modulating therapies such as the CGRP monoclonal antibodies.Keywords: ubrogepant, CGRP, migraine, Phase III trials, real-world
